Tumors are not just masses of rogue cells; they are hostile metabolic arenas where cancer cells and immune cells fight over the same dwindling supplies of glucose, oxygen and amino acids. A new systematic bibliometric review published in Frontiers in Oncology has mapped, for the first time at global scale, how scientific research on this tumor immunometabolism–cancer immunotherapy nexus has exploded over the past quarter century — and how the field has quietly pivoted from describing metabolic warfare to engineering it for therapeutic advantage.
The study, led by Jingshuai Huang, Haiyuan Zhong and colleagues at the First and Second Affiliated Hospitals of Guangxi Medical University in Nanning, China, searched the Web of Science Core Collection and Scopus databases on 26 July 2026 for English-language articles and reviews published between 2001 and 2025 that linked cancer, immune-cell metabolism and immunotherapy. Following the PRISMA 2020 reporting framework, the team applied prespecified eligibility criteria independently to each database, retaining 3,214 Web of Science records and 3,513 Scopus records. Rather than pooling the two corpora, the researchers analyzed them separately, using Scopus as an independent validation of every major trend detected in the primary dataset.
The headline finding is a field growing at breakneck speed. Web of Science indexed just four eligible papers in 2002 and only 44 cumulatively by 2009. Annual production climbed to 42 papers in 2015, 125 in 2019 and 245 in 2020, before surging to 774 papers in 2025. Strikingly, 83.7 percent of the entire Web of Science corpus was published between 2020 and 2025, and Scopus reproduced the same pattern almost exactly, with 83.0 percent of its records falling in the same window. In other words, more than four-fifths of everything humanity has published on tumor immunometabolism and immunotherapy appeared in just the last six years.
The geography of this boom is uneven in revealing ways. China was the most prolific contributor by corresponding-author country, producing 1,470 publications — 45.7 percent of the Web of Science corpus — led by the Chinese Academy of Sciences with 128 papers, followed by Shanghai Jiao Tong University, Sun Yat-sen University and Fudan University. The United States contributed 727 publications but dominated on influence: American papers accumulated 70,049 total citations versus China’s 55,911, and averaged 96.4 citations per article compared with China’s 38.0. The United Kingdom showed the highest rate of international collaboration among leading countries, with 57.4 percent of its papers involving authors from multiple nations, compared with just 12.0 percent for China. Publication volume, international connectedness and citation impact, the authors note, are three distinct dimensions of scientific leadership that do not necessarily travel together.
Behind the numbers lies a conceptual transformation that the researchers traced through citation bursts and keyword evolution. The field’s intellectual foundations rest on landmark 2015 Cell studies: Chang and colleagues demonstrated that metabolic competition in the tumor microenvironment drives cancer progression, while Ho and colleagues identified the metabolite phosphoenolpyruvate as a checkpoint governing antitumor T-cell responses. The former paper remains the most cited record in the corpus, with 2,727 global citations. Early keyword bursts centered on hypoxia, adenosine and nutrient deprivation — the explanatory vocabulary of a field cataloguing how tumors starve and poison immune cells.
The middle phase of the field’s evolution connected those metabolic conditions to immunotherapy mechanics. Researchers showed that PD-1 signaling suppresses glycolytic reprogramming in T cells while promoting fatty-acid oxidation, and that hypoxia-inducible factor signaling links oxygen deprivation directly to PD-L1 expression and immune suppression by myeloid cells. Glutamine blockade experiments revealed that a single metabolic intervention can push tumor cells and immune cells in opposite directions — a conceptual route to overcoming immune evasion. In parallel, studies of chimeric antigen receptor design showed that costimulatory domains determine the metabolic program and memory development of CAR-T cells, making metabolism a design variable rather than a background constraint.
The most recent and fastest-growing phase, reflected in the citation-burst literature, focuses on T-cell exhaustion, mitochondrial fitness, regulatory T-cell adaptation and metabolically engineered cellular therapies. Studies have shown that hypoxia-induced mitochondrial stress rapidly drives dysfunctional T-cell states, that lactic acid — long dismissed as waste — actually fuels tumor-infiltrating regulatory T cells and promotes PD-1 expression in highly glycolytic tumors, and that the mitochondrial pyruvate carrier regulates memory T-cell differentiation and antitumor function. CAR-T research has become the clearest engineering branch, with work spanning mitochondrial state, kynurenine degradation, endothelial serine metabolism, branched-chain amino-acid routing and even the surprising finding that CAR extracellular domains reprogram T-cell metabolism without antigen stimulation.
The keyword statistics quantify this shift. Immunotherapy was the most frequent author keyword with 768 occurrences, followed by tumor microenvironment (469), metabolism (198), T cells (187), immunometabolism (155), hypoxia (149), metabolic reprogramming (133), immune checkpoint inhibitors (121) and CAR-T cells (101). The trajectories accelerated sharply after 2020: annual use of immunotherapy rose from 51 in 2020 to 187 in 2025, metabolic reprogramming jumped from three occurrences to 58, immune checkpoint inhibitors from 12 to 32, and CAR-T cells from seven to 28. A co-occurrence network of 64 threshold-eligible keywords organized into six interconnected clusters linking T-cell activation and exhaustion, myeloid polarization, hypoxic microenvironments, checkpoint blockade, cellular therapies and biomarker applications — with metabolism and immunotherapy terms co-occurring rather than forming separate conceptual islands.
The authors are careful to draw a bright line between bibliometric trends and clinical reality. Keyword frequency and citation bursts show rapid adoption of translational terminology, they caution, but proximity to clinical language is not evidence of clinical efficacy or regulatory readiness. Most of the mechanism and engineering work remains preclinical or early translational, and the review’s critical reading highlights real weaknesses: measurement practice relies far more on transcriptional signatures and bulk-tissue abundance than on flux measurement or spatial metabolite mapping, positive findings dominate over neutral and negative results, and the author co-authorship network remains fragmented — 27 leading authors spread across 14 clusters with only 23 links — suggesting that laboratory pathway work and clinically anchored datasets are being produced by largely separate communities.
The review closes with a roadmap for the field’s next stage: integrating spatial metabolite mapping, isotope tracing and single-cell profiling to obtain cell-specific metabolic measurements; evaluating metabolic interventions as ecosystem-wide perturbations that affect tumors, effector T cells, regulatory T cells and normal tissues in different directions; building manufacturing-to-tumor continuity into cellular therapies by testing release criteria that include mitochondrial reserve and substrate flexibility; and prospectively distinguishing predictive metabolic biomarkers from safe causal intervention targets. The bibliometric record, the authors conclude, supports a clear translation-oriented shift in the literature — but converting metabolic insight into patient benefit will demand exactly the kind of rigorous, collaborative and measurement-driven work that the field’s fragmented structure has so far made rare.
Subject of Research: Bibliometric analysis of global research trends linking tumor immunometabolism and cancer immunotherapy from 2001 to 2025
Article Title: Worldwide research trends on the tumor immunometabolism–cancer immunotherapy nexus: a systematic bibliometric review
Article References: Huang, J., Zhong, H., Li, L., Wang, X., Lai, Y., Li, J., Jiang, D., & Lai, M. (2026). Worldwide research trends on the tumor immunometabolism–cancer immunotherapy nexus: a systematic bibliometric review. Frontiers in Oncology, 16, Article 1962391. https://doi.org/10.3389/fonc.2026.1962391
Image Credits: AI Generated
DOI: 10.3389/fonc.2026.1962391
Keywords: tumor immunometabolism, cancer immunotherapy, bibliometrics, tumor microenvironment, immune checkpoint inhibitors, CAR-T cells, metabolic reprogramming, T-cell exhaustion, hypoxia, lactate, mitochondrial fitness, Web of Science
News Source: Nathaniel Bowman. (October 19, 2026). Cancer’s Metabolic Battleground: How Immunometabolism Became Immunotherapy’s Next Frontier. Scienmag.
